Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry.

Dilute-and-shoot High resolution mass spectrometry Liquid chromatography Meldonium Screening method Solid-phase extraction

Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
20 Feb 2021
Historique:
received: 23 09 2020
revised: 09 12 2020
accepted: 21 12 2020
pubmed: 17 1 2021
medline: 22 6 2021
entrez: 16 1 2021
Statut: ppublish

Résumé

Considering the huge amount of substances associated with athletic performance improvement, current doping control analysis requires a comprehensive screening method, which leads to the detection of prohibited substances of different physico-chemical properties. This comprehensiveness associated with instrumental approaches based on high resolution mass spectrometry has allowed the development of extremely sensitive and selective detection methods. Furthermore, it is desirable the method to be simple, fast and straightforward. Mildronate is a highly polar quaternary amine, classified as metabolic modulator by the World Anti-Doping Agency (WADA). The inclusion of mildronate in the screening strategy is a challenge considering its singular physicochemical properties, compared to numerous doping agents of low and medium polarity. For this purpose, a method combining solid-phase extraction (SPE) and dilute-and-shoot approach has been developed and validated, allowing the detection of mildronate and other 332 prohibited substances. In the sample preparation protocol, the enzymatic deconjugation step and SPE conditions were stressed to enable the recovery of mildronate without jeopardizing the detection of other doping agents. The C

Identifiants

pubmed: 33453569
pii: S0731-7085(20)31757-X
doi: 10.1016/j.jpba.2020.113870
pii:
doi:

Substances chimiques

Methylhydrazines 0
3-(2,2,2-trimethylhydrazine)propionate 73H7UDN6EC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113870

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no competing interests.

Auteurs

Daniely Oliveira (D)

Brazilian Doping Control Laboratory 'LBCD-LADETEC', Av. Horácio Macedo 1281 Cidade Universitária, 21941-598, Rio de Janeiro, Brazil. Electronic address: daniely.oliveira@iq.ufrj.br.

Amanda de Araújo (A)

Brazilian Doping Control Laboratory 'LBCD-LADETEC', Av. Horácio Macedo 1281 Cidade Universitária, 21941-598, Rio de Janeiro, Brazil.

William Ribeiro (W)

Brazilian Doping Control Laboratory 'LBCD-LADETEC', Av. Horácio Macedo 1281 Cidade Universitária, 21941-598, Rio de Janeiro, Brazil.

Daniele Silva (D)

Brazilian Doping Control Laboratory 'LBCD-LADETEC', Av. Horácio Macedo 1281 Cidade Universitária, 21941-598, Rio de Janeiro, Brazil.

Ana Carolina Duarte (AC)

Brazilian Doping Control Laboratory 'LBCD-LADETEC', Av. Horácio Macedo 1281 Cidade Universitária, 21941-598, Rio de Janeiro, Brazil.

Valeria de Sousa (V)

Federal University of Rio de Janeiro, Department of Drugs and Pharmaceutics, Av. Carlos Chagas Filho 373 Cidade Universitária, 21941-170, Rio de Janeiro, Brazil.

Henrique Gualberto Pereira (HG)

Brazilian Doping Control Laboratory 'LBCD-LADETEC', Av. Horácio Macedo 1281 Cidade Universitária, 21941-598, Rio de Janeiro, Brazil.

Articles similaires

Humans Chromatography, High Pressure Liquid Acetaminophen COVID-19 SARS-CoV-2
Humans Pisum sativum Breast Neoplasms Tandem Mass Spectrometry Plant Extracts
Humans Breast Neoplasms Female Mass Spectrometry Adipose Tissue
Humans Proteomics Paraffin Embedding Tissue Fixation Organelles

Classifications MeSH